MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas

Autor: Tomohiro Hosoya, Masamichi Takahashi, Mai Honda-Kitahara, Yasuji Miyakita, Makoto Ohno, Shunsuke Yanagisawa, Takaki Omura, Daisuke Kawauchi, Yukie Tamura, Miyu Kikuchi, Tomoyuki Nakano, Akihiko Yoshida, Hiroshi Igaki, Yuko Matsushita, Koichi Ichimura, Yoshitaka Narita
Rok vydání: 2022
Předmět:
Zdroj: Journal of Neuro-Oncology. 157:561-571
ISSN: 1573-7373
0167-594X
Popis: Purpose Although the usefulness of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation analysis for predicting response to chemoradiotherapy and the prognosis of patients with glioblastoma has been widely reported, there is still no consensus regarding how to define MGMT promoter methylation percentage (MGMTpm%) cutoffs by pyrosequencing method. The aim of this study was to determine the optimal cutoff value of MGMT promoter methylation status using volumetric analysis focused on the tumor volume ratio (TVR) measured by MRI. Methods This retrospective study included newly diagnosed IDH wild-type glioblastoma patients with residual tumor after surgery, followed by local radiotherapy with temozolomide. TVR was defined as the tumor volume at 6 months after the initial chemoradiotherapy administration divided by the tumor volume before the start of therapy. The mean MGMTpm% of 16 CpG islands (74–89) was analyzed using pyrosequencing. We statistically analyzed the correlation between MGMTpm%, TVR, and change in Karnofsky performance status. Results The study included 44 patients with residual tumors. Thirteen (92.9%) of 14 patients with MGMTpm% ≥ 23.9% showed 50% or more volumetric response, leading to prolonged survival, and 17 (70.8%) of 24 patients with MGMTpm% Conclusion Evaluation of MGMTpm% by pyrosequencing is important in predicting the volumetric response and prognosis of glioblastoma patients with residual tumors.
Databáze: OpenAIRE
Externí odkaz: